Small Pharma
Pipeline of novel patent-protected deuterium-enriched tryptamine compounds for psychedelic-assisted psychotherapy as a rapid onset, sustained treatment for mental health disorders.
Launch date
Employees
Market cap
AUD57.1m
Enterprise valuation
AUD43m (Public information from Oct 2023)
Share price
CAD0.15 DMT.V
Company register number 09420724
London England (HQ & founding location)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | <1m | <1m | - | - |
| % growth | - | 4 % | - | - |
| EBITDA | (4.0m) | (3.7m) | (12.0m) | (16.4m) |
| % EBITDA margin | (8000 %) | (7232 %) | - | - |
| Profit | - | (4.7m) | (14.8m) | (15.2m) |
| % profit margin | - | (9061 %) | - | - |
| R&D budget | - | 1.3m | 3.2m | 7.6m |
| R&D % of revenue | - | 2473 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
£830k | Seed | ||
* | N/A Valuation: CAD240m 3200.0x EV/LTM Revenues -40.0x EV/LTM EBITDA | IPO | |
* | N/A | Acquisition | |
| Total Funding | AUD1.7m | ||
Related Content
Recent News about Small Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.